.Merck & Co.'s TIGIT course has actually gone through yet another drawback. Months after shutteri...
.After a year specified by pipeline cuts, the departure of its chief executive officer and cutbacks,...
.Cullinan Therapy was actually made an impression on good enough along with Port BioMed's bispecific...
.In this particular full week's episode of "The Best Pipe," our company are actually diving in to Fe...
.The confetti is actually still flying coming from Eli Lilly's event celebrating the approval of Alz...
.Welcome to this week's Chutes & Ladders, our summary of considerable management hirings, shootin...
.Following an unsatisfactory presenting for Lykos Rehabs' MDMA applicant for post-traumatic stress d...
.AN2 Therapeutics is actually reconsidering its own business in action to uninspired midphase data, ...
.Merck & Co. is actually spending $700 thousand upfront to challenge Amgen in a blood cancer cell...
.With Gilead Sciences on the verge of an FDA choice for its own liver ailment drug seladelpar, the p...